INSIGHTS ON DRUG DEVELOPMENT
-
Formulation Strategies For Enabling "Undevelopable" Compounds
KinetiSol enhances bioavailability of poorly soluble drugs like Vemurafenib by producing dense amorphous dispersions, outperforming traditional MBP methods in pharmacokinetics and dissolution.
-
PAT Implementation For ADC And Bioconjugation Processes
Explore expert insights into the implementation of Process Analytical Technology (PAT) for ADC and bioconjugation processes and the pros and cons of in(on)line testing for the conjugation process.
-
Little Patients, Big Challenges: Developing Pediatric Formulations
Explore the development of high-quality, child-friendly oral formulations, as well as learn about new testing requirements for impurities and innovative approaches to creating age-appropriate medications.
-
Characterization And Impurity Profiling Of Combined Amylin And GLP-1 Analogs
GLP-1 receptor agonists are transforming diabetes and weight loss treatment. Discover how to enable precise impurity analysis and characterization of complex, fatty acid-modified peptide therapeutics.
-
The Complete Guide To Immunohistochemistry9/24/2024
Immunohistochemistry (IHC) is a tool for visualizing the distribution and localization of antigens within tissue sections. Learn about IHC sample preparation, detection and amplification systems, and more.
-
Digital Transformation Essentials: AI Readiness, What Do You Need To Know?6/22/2024
Unlock the full potential of AI and digital solutions with these practical steps to begin moving your BioPharma organization's goals forward with optimized data usage.
-
Assessing Viability And Real-Time Apoptosis/Necrosis3/17/2025
Malignant gliomas are aggressive brain tumors that resist standard treatments. Discover why researchers focus on real-time cell death dynamics to develop targeted therapies and promising strategies.
-
A Tale Of Two Brothers: The Abpro Founders12/11/2023
By founding their latest venture, Abpro, Ian and Eugene Chan are using their synergistic skillsets in business and medicine to rapidly generate antibodies that treat cancer and autoimmune diseases.
-
Amorphous Stability: Mesoporous Silica For Poor Glass Formers6/5/2025
Discover how mesoporous silica outperforms polymeric solid dispersions in stabilizing poor glass formers, as well as how it offers a novel approach to enhance amorphous drug stability and bioavailability.
DRUG DEVELOPMENT SOLUTIONS
-
Dissection Perfection
Laser Microdissection (LMD, also known as Laser Capture Microdissection or LCM) enables users to isolate specific single cells or entire areas of tissue. Powered by a unique laser design and dynamic software, Leica LMD systems allow users to easily isolate Regions of Interest (ROI) from entire areas of tissue down to single cells or even subcellular structures such as chromosomes.
-
Leica DM300
For slightly more advanced students in biology or 2-4 year college life science classrooms, the Leica DM300 compound microscope is compact, maintenance-free and easy to use to provide trouble free operation each day.
Equipped with a mechanical stage to accommodate two specimen slides and labelled Abbe condenser, the DM300 can be configured with rotatable monocular or binocular tubes for shared viewing and easy storage. Trinocular tube is also possible to go digital.
With 165 years of microscope design and manufacturing experience, the Leica DM300 student microscope provides students with the capabilities they need to study the finest details in all the Life Sciences.
-
Highly potent APIs require stringent containment and precise manufacturing controls. Specialized facilities offer end-to-end development solutions and robust cross-contamination protections.
-
Enhance your research and obtain exceptional imaging and analysis with a configurable and upgradeable high-content screening system that captures high-definition images and robust data from 2D and 3D assays.
-
Re-engineer your drug's path into clinical development and accelerate time to Proof-of-Concept. Real-time data guides rapid formulation iterations, minimizing drug substance use and lowering program risk.